{"id":"anti-il12-23-or-anti-il23-risankizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Risankizumab binds to the p19 subunit of IL-23, a key cytokine involved in driving Th17 cell differentiation and inflammatory responses. By specifically inhibiting IL-23 (rather than the broader IL-12/23 pathway), it reduces pathogenic inflammation while preserving some immune function. This selective mechanism has shown efficacy in inflammatory skin and bowel conditions driven by IL-23-mediated immunity.","oneSentence":"Risankizumab is a monoclonal antibody that selectively blocks the IL-23 cytokine pathway to reduce inflammatory immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:27.618Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT06274554","phase":"PHASE3","title":"Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2024-10-04","conditions":"Crohn's Disease, Inflammatory Bowel Diseases","enrollment":120},{"nctId":"NCT07041112","phase":"","title":"Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors","status":"COMPLETED","sponsor":"Juan Ruano Ruiz","startDate":"2012-01-01","conditions":"Psoriasis, Psoriatic Arthritis (PsA), Cardiovascular Risk Factors","enrollment":1000},{"nctId":"NCT05928039","phase":"PHASE4","title":"PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2023-10-25","conditions":"Crohn Disease","enrollment":297}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":111,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Anti-IL12/23 or anti-IL23 - Risankizumab","genericName":"Anti-IL12/23 or anti-IL23 - Risankizumab","companyName":"University of Calgary","companyId":"university-of-calgary","modality":"Biologic","firstApprovalDate":"","aiSummary":"Risankizumab is a monoclonal antibody that selectively blocks the IL-23 cytokine pathway to reduce inflammatory immune responses. Used for Moderate to severe plaque psoriasis, Crohn's disease, Ulcerative colitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}